Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Total Current Liabilities (2020 - 2025)

Caribou Biosciences has reported Total Current Liabilities over the past 6 years, most recently at $25.4 million for Q4 2025.

  • Quarterly Total Current Liabilities fell 17.09% to $25.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.4 million through Dec 2025, down 17.09% year-over-year, with the annual reading at $25.4 million for FY2025, 17.09% down from the prior year.
  • Total Current Liabilities was $25.4 million for Q4 2025 at Caribou Biosciences, down from $28.1 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $34.4 million in Q2 2023 and troughed at $24.6 million in Q3 2023.
  • The 5-year median for Total Current Liabilities is $28.3 million (2023), against an average of $28.3 million.
  • Year-over-year, Total Current Liabilities surged 108.48% in 2021 and then dropped 17.09% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $25.8 million in 2021, then grew by 8.9% to $28.1 million in 2022, then grew by 0.62% to $28.3 million in 2023, then increased by 8.3% to $30.7 million in 2024, then dropped by 17.09% to $25.4 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Total Current Liabilities are $25.4 million (Q4 2025), $28.1 million (Q3 2025), and $28.9 million (Q2 2025).